statut_color,statut,statut_name,NCTId,eudraCT,CTIS,completion_year,clinical_trial_title,acronym,intervention_type
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2008-004707-59,,2009,"A phase II study of CP-751,871 in patients with recurrent and/or metastatic squamous head and neck carcinoma",IGF-1R protocol,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,NCT00405210,,,2009,"Open-label, Multicenter,PhaseI Trial in Order To Determine the Safety and Pharmacokinetics of BAY43-9006 in Combination With Docetaxel as First-line Treatment in Metastatic Hormone Refractory Prostate Cancer Patients",,DRUG
üü•,3,3 : r√©sultats post√©s ou publi√©s apr√®s les 36 mois,,2008-004575-21,,2012,"A single arm, multicenter, phase II trial of RAD001 as monotherapy in the palliative treatment of patient with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy",,DRUG (presumed)
‚¨õ,4,4 : pas de r√©sultats post√©s ni publi√©s,,2015-001703-32,,,Phase III multicentric study evaluating the efficacy and safety of sirolimus in Vascular Anomalies that are refractory to standard care,VASE,DRUG (presumed)
